Expert Opinion on Therapeutic Patents

Papers
(The H4-Index of Expert Opinion on Therapeutic Patents is 23. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-04-01 to 2025-04-01.)
ArticleCitations
Patent landscape of small molecule inhibitors of METTL3 (2020-present)50
Dipeptidyl peptidase IV inhibitors as a potential target for diabetes: patent review 2019 – present46
Vasopressin receptor antagonists: a patent summary (2018-2022)43
Trispecific anti-CD3/BCMA/CD38 antibodies for multiple myeloma: a patent evaluation of US2024013261536
Malaria transmission blocking compounds: a patent review36
A patent review of adenosine A2Breceptor antagonists (2016-present)36
Dopamine D3 receptor ligands: a patent review (2014–2020)33
Peroxisome Proliferator-Activated Receptor agonists and antagonists: an updated patent review (2020–2023)32
Synthetic molecules as DprE1 inhibitors: A patent review30
Exploring drug patent linkage and the first ANDA litigation in China30
Antimalarial drugs: what’s new in the patents?30
Mucormycosis medications: a patent review29
Update on mGlu4 modulator patents: 2017 to present28
Steroid sulfatase inhibitors: the current landscape27
A patent review of topoisomerase I inhibitors (2016–present)27
Dihydrofolate reductase inhibitors: patent landscape and phases of clinical development (2001–2021)27
Selective estrogen receptor degraders (SERDs) and covalent antagonists (SERCAs): a patent review (July 2021–December 2023)25
Synthesis and therapeutic delivery approaches for praziquantel: a patent review (2010-present)25
Menin-MLL protein–protein interaction inhibitors: a patent review (2021-present)24
Recent developments of agents targeting Vibrio cholerae : patents and literature data24
BET inhibitors: an updated patent review (2018–2021)23
An updated patent review of matrix metalloproteinase (MMP) inhibitors (2021-present)23
Targeting the EGFR/RAS/RAF signaling pathway in anticancer research: a recent update on inhibitor design and clinical trials (2020–2023)23
0.043743848800659